Masonic Cancer Center, University of Minnesota to Present Data in Poster Presentation From the Phase 1 Clinical Trial to Evaluate HCW9218 in Solid Tumors At the SITC 37th Annual Meeting
08 Novembro 2022 - 9:00AM
HCW Biologics Inc. (the “Company” or “HCW Biologics”) (NASDAQ:
HCWB), a clinical-stage biopharmaceutical company focused on
discovering and developing novel immunotherapies to lengthen
healthspan by disrupting the link between inflammation and
age-related diseases, today announced that data will be presented
at the 37th Annual Meeting of the Society for Immunotherapy of
Cancer (“SITC”) from an ongoing Phase 1 clinical trial to evaluate
HCW9218 in patients with chemo-refractory/chemo-resistant solid
tumors, conducted by the Masonic Cancer Center, University of
Minnesota. A poster will be presented by Melissa A. Geller, M.D.,
M.S., Professor and Division Director of Gynecologic Oncology in
the Department of Obstetrics, Gynecology and Women’s Health at the
University of Minnesota who serves as a Principal Investigator of
this trial.
HCW Biologics has also initiated a
Company-sponsored Phase 1b/2 clinical trial in patients with
chemo-refractory/chemo-resistant pancreatic cancer and dosed two
patients in October 2022. The Company selected
chemo-refractory/chemo-resistant solid tumors for its first
clinical indications because solid tumor cancers are characterized
by a dense fibrotic stroma or desmoplasia that allows a tumor to
shield itself from standard-of-care treatment, such as chemotherapy
and immune-checkpoint inhibitors. The immunosuppressive growth
factor, TGF-β, plays a major role in formation of desmoplasia and
promoting tumor growth and metastasis. HCW9218 is an
injectable, bifunctional fusion protein complex designed to
simultaneously stimulate effector T cell and natural killer cell
responses and inhibit the activity of TGF-β and its
immunosuppressive effect. The Company believes these combined
capabilities may define a new category of cancer treatment
accomplished by modifying factors related to drug resistance and
disease recurrence, especially for the most difficult to treat
cancers that are chemo-refractory/chemo-resistant.
Details of the presentation are as follows:
Title: A phase I study of
HCW9218, a bifunctional TGF-β antagonist/IL-15 protein complex, in
advanced solid tumorsPresentation
Type: Poster
724Presenter: Melissa A. Geller, M.D., M.S.,
Professor and Division Director of Gynecologic Oncology in the
Department of Obstetrics, Gynecology and Women’s Health at the
University of MinnesotaLocation: Poster
HallDate/Time: November 10, 2022, 9 a.m. to 9
p.m., Eastern Time and November 11, 2022, 9 a.m. to 8:30 p.m.,
Eastern Time
The presentation will be made available on the
Company’s website in the Investors section under Events &
Presentations, following the conference.
For conference information, visit
www.sitcancer.org/2022/program/annual-meeting.
About the HCW9218 Phase 1 Clinical Trial
Sponsored by Masonic Cancer CenterThis Phase 1,
first-in-human clinical trial is enrolling patients that have
advanced solid tumors with progressive disease after prior
chemotherapies. The trial is led by University of Minnesota
oncologist Melissa Geller, MD, MS, Professor, and Division
Director, Gynecologic Oncology, Department of Obstetrics,
Gynecology and Women's Health (OBGYN) in the Medical School and the
Masonic Cancer Center’s Associate Director for Clinical Research,
with collaboration from Jeffrey Miller, MD, Professor of Medicine
in the Medical School’s Division of Hematology, Oncology and
Transplantation and Deputy Director of the Masonic Cancer Center,
and Manish Patel, DO, Associate Professor of Medicine, Division of
Hematology, Oncology and Transplantation and Director of the
Developmental Therapeutics Clinic. See clinicaltrials.gov
Identifier: NCT05322408.
About Masonic Cancer Center:The
Masonic Cancer Center, University of Minnesota, is the Twin Cities’
only Comprehensive Cancer Center, designated ‘Outstanding’ by the
National Cancer Institute. As Minnesota’s Cancer Center, they have
served the entire state for more than 25 years. Their researchers,
educators, and care providers have worked to discover the causes,
prevention, detection, and treatment of cancer and cancer-related
diseases.
About HCW Biologics:
HCW Biologics is a clinical-stage
biopharmaceutical company focused on discovering and developing
novel immunotherapies to lengthen healthspan by disrupting the link
between chronic, low-grade inflammation, and age-related diseases,
such as cancer, cardiovascular diseases, diabetes,
neurodegenerative diseases, and autoimmune diseases. The Company
has combined deep understanding of disease-related immunology with
its expertise in advanced protein engineering to develop the TOBI™
(Tissue factOr-Based fusIon) discovery platform. The Company uses
its TOBITM discovery platform to generate designer, novel
multi-functional fusion molecules with immunotherapeutic
properties. The invention of HCW Biologics’ two lead molecules,
HCW9218 and HCW9302, was made via the TOBI™ discovery platform. The
Masonic Cancer Center, University of Minnesota, has initiated a
Phase 1 clinical trial to evaluate HCW9218 in
chemo-refractory/chemo-resistant solid tumors that have progressed
after prior chemotherapies. The Company has initiated a
Company-sponsored Phase 1b/2 clinical trial to evaluate HCW9218 in
chemo-refractory/chemo-resistant advanced pancreatic cancer. The
Company’s lead molecule for its regulatory T cell expansion
program, HCW9302, is currently undergoing IND-enabling studies for
an autoimmune indication.
Forward Looking
Statements:Statements in this press release contain
“forward-looking statements” that are subject to substantial risks
and uncertainties. These statements are made under the “safe
harbor” provisions of the U.S. Private Securities Litigation Reform
Act of 1995. Forward-looking statements contained in this press
release may be identified by the use of words such as “anticipate,”
“expect,” “believe,” “will,” “may,” “should,” “estimate,”
“project,” “outlook,” “forecast” or other similar words and
include, without limitation, statements regarding HCW9218 being a
new category of cancer treatment capable of modifying factors
related to drug resistance and disease recurrence; the ability of
HCW9218 to treat cancer; and the ability of HCW9218 to neutralize
TGF-β and the Company’s ability to provide an early human data
readout. Forward-looking statements are based on the Company’s
current expectations and are subject to inherent uncertainties,
risks and assumptions that are difficult to predict. Further,
certain forward-looking statements are based on assumptions as to
future events that may not prove to be accurate. Factors that could
cause actual results to differ include, but are not limited to, the
risks and uncertainties that are described in the section titled
“Risk Factors” in the Company’s Quarterly Report on Form 10-Q filed
with the United States Securities and Exchange Commission (the
“SEC”) on November 7, 2022 and in other filings filed from time to
time with the SEC. Forward-looking statements contained in this
press release are made as of this date, and the Company undertakes
no duty to update such information except as required under
applicable law.
Company Contact:Rebecca
ByamCFOHCW Biologics Inc.rebeccabyam@hcwbiologics.com
HCW Biologics (NASDAQ:HCWB)
Gráfico Histórico do Ativo
De Mai 2024 até Jun 2024
HCW Biologics (NASDAQ:HCWB)
Gráfico Histórico do Ativo
De Jun 2023 até Jun 2024